Efficacy of syringomycin E in a murine model of vaginal candidiasis
- PMID: 9766466
- DOI: 10.7164/antibiotics.51.743
Efficacy of syringomycin E in a murine model of vaginal candidiasis
Abstract
Syringomycin E (SR-E), a new antifungal produced by the bacterium Pseudomonas syringae pv. syringae, was evaluated in a murine vaginal candidiasis model. In one study, mice were treated intravaginally b.i.d. for 4 days with drug carrier, SR-E 2% in either PEG-400 or PEG-ointment, or 1% clotrimazole as a positive control. Quantitative vaginal cultures were taken prior to treatment on day 1 and on days 5, 6, and 7. Both formulations showed a reduction of yeast colonization in the vaginas on day 5 (P< or =0.06 and P< or =0.03 for SR-E/PEG-400 and SR-E/PEG ointment, respectively) and SR-E/PEG ointment reduced the colonization on day 7 (P< or =0.06) when compared to carrier treated controls. In a second study, SR-E was formulated in Aquaphor at three higher concentrations of SR-E [3%, 6%, or 12% (w/v)]. SR-E showed dose-dependent efficacy. The 3% dose showed no effect while the 6% and 12% doses reduced the number of yeasts. The 12% dose showed a significant reduction on days 5 (P< or =0.01), 6 (P< or =0.06), and 7 (P< or =0.03) when compared with the drug carrier controls and on day 5 was more effective than clotrimazole (P< or =0.03). Clotrimazole did not significantly reduce the yeasts in the vagina until days 6 (P< or =0.01) and 7 (P< or =0.01) when compared to the drug carrier controls. No vaginal inflammatory response was evident by histological examination in uninfected animals treated with SR-E. No SR-E could be detected in plasma, kidney, or liver. SR-E (12%) was an effective treatment when compared to 1% clotrimazole.
Similar articles
-
Comparison of vaginal ointment of honey and clotrimazole for treatment of vulvovaginal candidiasis: A random clinical trial.J Mycol Med. 2017 Dec;27(4):494-500. doi: 10.1016/j.mycmed.2017.07.003. Epub 2017 Jul 29. J Mycol Med. 2017. PMID: 28760590 Clinical Trial.
-
Three-day treatment with butoconazole vaginal suppositories for vulvovaginal candidiasis.J Reprod Med. 1986 Feb;31(2):131-2. J Reprod Med. 1986. PMID: 3514908 Clinical Trial.
-
Evaluation of vaginal antifungal formulations in vivo.Postgrad Med J. 1979 Sep;55(647):648-52. doi: 10.1136/pgmj.55.647.648. Postgrad Med J. 1979. PMID: 392480 Free PMC article.
-
Interventions for prevention and treatment of vulvovaginal candidiasis in women with HIV infection.Cochrane Database Syst Rev. 2011 Aug 10;(8):CD008739. doi: 10.1002/14651858.CD008739.pub2. Cochrane Database Syst Rev. 2011. PMID: 21833970 Review.
-
Clotrimazole: a review of its antifungal activity and therapeutic efficacy.Drugs. 1975;9(6):424-47. doi: 10.2165/00003495-197509060-00003. Drugs. 1975. PMID: 1097234 Review.
Cited by
-
Antimicrobial peptides: versatile biological properties.Int J Pept. 2013;2013:675391. doi: 10.1155/2013/675391. Epub 2013 Jun 26. Int J Pept. 2013. PMID: 23935642 Free PMC article.
-
Syringomycin E inhibition of Saccharomyces cerevisiae: requirement for biosynthesis of sphingolipids with very-long-chain fatty acids and mannose- and phosphoinositol-containing head groups.Antimicrob Agents Chemother. 2000 May;44(5):1174-80. doi: 10.1128/AAC.44.5.1174-1180.2000. Antimicrob Agents Chemother. 2000. PMID: 10770748 Free PMC article.
-
Fungal lethality, binding, and cytotoxicity of syringomycin-E.Antimicrob Agents Chemother. 1999 Feb;43(2):371-3. doi: 10.1128/AAC.43.2.371. Antimicrob Agents Chemother. 1999. PMID: 9925536 Free PMC article.
-
Peptide-based Antifungal Therapies against Emerging Infections.Drugs Future. 2010 Mar;35(3):197. doi: 10.1358/dof.2010.035.03.1452077. Drugs Future. 2010. PMID: 20495663 Free PMC article.
-
Genetic susceptibility of mice to Candida albicans vaginitis correlates with host estrogen sensitivity.Infect Immun. 2004 Aug;72(8):4878-80. doi: 10.1128/IAI.72.8.4878-4880.2004. Infect Immun. 2004. PMID: 15271952 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Research Materials
